» Articles » PMID: 10873082

Comparison of Potential Markers of Farnesyltransferase Inhibition

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2000 Jun 29
PMID 10873082
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Farnesyltransferase inhibitors (FTIs) were developed to target abnormal signaling pathways that are commonly activated in neoplastic cells. Five FTIs have recently undergone Phase I testing; and two are currently in Phase II clinical trials. As part of the development of these agents, there has been interest in determining their cellular effects in the clinical setting. Several approaches have been proposed, including measurement of FT enzymatic activity, evaluation of the processing of FT polypeptide substrates, and assessment of the accumulation of p21waf1. In the present study, a number of these assays have been compared in four cultured human neoplastic cell lines of different histology (A549, HCT116, BxPC-3, and MCF-7) after treatment with the nonpeptidomimetic FTI SCH66336 and the peptidomimetic inhibitor FTI-277. Immunoblotting studies failed to demonstrate a mobility shift in ras proteins or increased accumulation of p21waf1 after treatment with these agents. In contrast, drug-induced increases in the slower migrating, unprocessed species of the chaperone protein HDJ-2 and the intranuclear intermediate filament protein lamin A were detected in all four cell lines after treatment with either agent. Unprocessed forms of both polypeptides accumulated in noncycling as well as cycling cells. The precursor peptide that is present in prelamin A but absent from mature lamin A could be readily detected by immunohistochemistry in noncycling cells with a peptide-specific antiserum. Our results indicate that unprocessed HDJ-2 and prelamin A should be suitable markers of FT inhibition in clinical samples.

Citing Articles

Synthetic Small Molecule Modulators of Hsp70 and Hsp40 Chaperones as Promising Anticancer Agents.

Nitzsche B, Hopfner M, Biersack B Int J Mol Sci. 2023; 24(4).

PMID: 36835501 PMC: 9964478. DOI: 10.3390/ijms24044083.


Impaired Autophagic-Lysosomal Fusion in Parkinson's Patient Midbrain Neurons Occurs through Loss of ykt6 and Is Rescued by Farnesyltransferase Inhibition.

Pitcairn C, Murata N, Zalon A, Stojkovska I, Mazzulli J J Neurosci. 2023; 43(14):2615-2629.

PMID: 36788031 PMC: 10082462. DOI: 10.1523/JNEUROSCI.0610-22.2023.


Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice.

Cuddy L, Alia A, Salvo M, Chandra S, Grammatopoulos T, Justman C Mol Neurodegener. 2022; 17(1):54.

PMID: 35987691 PMC: 9392365. DOI: 10.1186/s13024-022-00561-9.


A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.

Jazieh K, Molina J, Allred J, Yin J, Reid J, Goetz M Invest New Drugs. 2018; 37(2):307-314.

PMID: 30171497 PMC: 9594493. DOI: 10.1007/s10637-018-0662-1.


HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation.

Efimova E, Ricco N, Labay E, Mauceri H, Flor A, Ramamurthy A Mol Cancer Ther. 2017; 17(2):407-418.

PMID: 29030460 PMC: 5805623. DOI: 10.1158/1535-7163.MCT-17-0288.